A supply crisis exposed growing demand for menopause treatment.
Madrid, Spain
Lenzetto, one of the most widely used hormonal treatments for menopause symptoms, is expected to return to Spanish pharmacies during the second half of November after months of shortages. Manufacturer Gedeon Richter has confirmed that supplies should begin to recover, although the company warns that global production constraints may continue to limit availability throughout 2027. The shortage has affected thousands of patients who rely on estradiol-based therapy and has placed additional pressure on alternative treatments. The problem reflects a broader transformation in demand for menopause care across Europe.
According to the manufacturer, the shortage was triggered by a much sharper increase in demand than anticipated. Production capacity and supplies of the applicator used to administer Lenzetto were unable to keep pace with consumption. The company stresses that the disruption is not linked to any quality or safety problem with the medicine. Instead, it is fundamentally a manufacturing and supply-chain challenge.
The consequences have extended beyond a single product. As patients and doctors shifted toward other estradiol-based treatments, demand increased for patches, gels and alternative formulations, creating shortages in products such as Evopad, Estradot and Bijuva. Spanish health authorities have therefore been forced to manage a wider therapeutic supply problem rather than an isolated shortage. The European Medicines Agency is also monitoring the situation as similar pressures affect several markets.
Spain has attempted different strategies to improve availability, including adjustments to regulated pricing and discussions with manufacturers of alternative hormone therapies. However, authorities acknowledge that pricing alone cannot solve a problem caused by limited manufacturing capacity. Catalonia has even prepared the possibility of allowing pharmacies to produce compounded estradiol formulations if industrial supplies remain insufficient. That option remains controversial because pharmaceutical authorities generally consider compounded preparations a last-resort solution.
Gedeon Richter says it is expanding production through additional suppliers, new manufacturing options and investment in facilities, including projects in Romania. Even so, pharmaceutical capacity cannot be increased instantly because new production lines must meet strict quality requirements before reaching the market. The company currently expects the supply situation to improve progressively rather than normalize immediately.
The shortage is therefore about more than one medication. It reveals how quickly healthcare systems can be strained when demand changes faster than pharmaceutical manufacturing networks can adapt. Menopause treatment is becoming more visible, more widely discussed and more frequently prescribed, but supply systems are still adjusting to that shift.
Healthcare access depends not only on medical innovation, but on the resilience of the supply chain behind it.